Evotec

EVO

Market cap $710M

Evotec SE (EVO) Q2 2026 Earnings Call Transcript

Evotec NASDAQ: EVO reported preliminary unaudited results for the second quarter and first half of 2026 and lowered its full-year outlook, citing delayed strategic partnership revenue, slower conversion of commercial activity into revenue and longer timelines for new partnership agreements.

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014  HAMBURG, Germany, July 13, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced preliminary unaudited financial results for the second quarter and first half of 2026 and updated its full-year 2026 outlook.

Expands Just – Evotec Biologics partner-enablement and technology licensing model for proprietary continuous manufacturing platform Enables deployment of continuous manufacturing platform in partner-owned facilities to support higher productivity and flexibility compared with fed-batch technology biologics manufacturing Modular manufacturing infrastructure, equipment and proprietary technology enable rapid and cost-efficient increase in capacity for biologics manufacturing SEATTLE and HAMBURG, Germany, June 30, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced the expansion of its Just – Evotec Biologics services with J.TRAIN, a new offering that enables biopharmaceutical companies to deploy Evotec's proprietary continuous manufacturing technology directly within their own facilities on a turnkey basis. J.TRAIN brings together prefabricated modular cleanrooms and industry-standard manufacturing equipment with Just – Evotec Biologics' cGMP-compliant process automation, designed to enable significantly faster and more cost-effective deployment than traditional manufacturing expansion.

11.06.2026 / 15:30 CET/CESTThe issuer is solely responsible for the content of this announcement. All agenda items adopted Dieter Weinand and Dr. Wolfgang Hofmann newly elected to the Supervisory Board Dieter Weinand appointed Chairman of the Supervisory Board Dr. Duncan McHale and Wesley Wheeler re‑elected to the Supervisory Board HAMBURG, Germany, June 11, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced the results of its Annual General Meeting.

HAMBURG, DE / ACCESS Newswire / June 2, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the appointment of Rui Wang as Executive Vice President, Head of Global In Silico and AI. Mr. Wang brings to Evotec more than 20 years of experience supporting global pharma and biotech organizations to embed scalable data, analytics & AI across R&D, drug development, manufacturing and supply chain functions.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH, OR TO PERSONS IN ANY JURISDICTION TO WHOM, SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. HAMBURG, GERMANY / ACCESS Newswire / May 12, 2026 / Evotec SE (the "Company" or "Evotec") (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) placed today senior unsecured convertible bonds due 2033, convertible into new and/or existing no-par value ordinary bearer shares of the Company (the "Shares"), in an aggregate principal amount of €116.1 million (the "Bonds").

Evotec SE (EVO) Q1 2026 Earnings Call Transcript

Joint Evotec-Almirall team advances small molecule program to preclinical development significantly outperforming standard industry timelines Collaboration leverages Evotec's end-to-end integrated AI/ML-driven R&D capabilities and Almirall's dermatology expertise HAMBURG, DE / ACCESS Newswire / May 4, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the nomination of a small molecule preclinical development candidate (PDC) from its multi‑target drug discovery alliance in medical dermatology with Almirall S.A. The program is aimed at developing novel treatments for immune‑mediated inflammatory skin diseases with high unmet medical need.

Grants support discovery and development of novel drug candidates and evaluation and prioritization of advanced drug regimens for clinical testing New funding from the Gates Foundation extends Evotec's commitment to create more effective tuberculosis treatment regimens HAMBURG, GERMANY / ACCESS Newswire / April 30, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced that it has received two grants from the Gates Foundation for drug discovery and translation in tuberculosis (TB), following four earlier TB grants from the foundation, amounting to $4.9 million over 25 months and $5 million over 24 months. The new funding underscores Evotec's commitment to translating innovative science into impactful therapies addressing high-priority public health threats.